WallStreetZenWallStreetZen

NASDAQ: ACAD
Acadia Pharmaceuticals Inc Stock

$24.61+0.71 (+2.97%)
Updated Jun 2, 2023
ACAD Price
$24.61
Fair Value Price
$25.32
Market Cap
$4.00B
52 Week Low
$12.24
52 Week High
$26.04
P/E
-27.04x
P/B
10.69x
P/S
5.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$520.23M
Earnings
-$145.94M
Gross Margin
98.3%
Operating Margin
-28.03%
Profit Margin
-28.1%
Debt to Equity
0.75
Operating Cash Flow
-$56M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

ACAD Overview

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ACAD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ACAD ($24.61) is undervalued by 2.8% relative to our estimate of its Fair Value price of $25.32 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
ACAD ($24.61) is not significantly undervalued (2.8%) relative to our estimate of its Fair Value price of $25.32 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
ACAD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more ACAD due diligence checks available for Premium users.

Be the first to know about important ACAD news, forecast changes, insider trades & much more!

ACAD News

Valuation

ACAD fair value

Fair Value of ACAD stock based on Discounted Cash Flow (DCF)
Price
$24.61
Fair Value
$25.32
Undervalued by
2.80%
ACAD ($24.61) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
ACAD ($24.61) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
ACAD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

ACAD price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-27.04x
Industry
11.51x
Market
52.74x

ACAD price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
10.69x
Industry
5.19x
ACAD is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

ACAD's financial health

Profit margin

Revenue
$118.5M
Net Income
-$43.0M
Profit Margin
-36.3%
ACAD's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ACAD's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$655.3M
Liabilities
$281.0M
Debt to equity
0.75
ACAD's short-term assets ($502.85M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACAD's short-term assets ($502.85M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACAD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ACAD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$17.9M
Investing
$192.5M
Financing
$1.5M
ACAD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ACAD vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
ACAD$4.00B+2.97%-27.04x10.69x
TGTX$3.97B-3.12%-21.77x144.64x
ABCM$3.88B+4.00%-375.56x4.42x
ARWR$3.85B+3.98%-25.39x8.63x
CYTK$3.69B+1.77%-8.38x-16.13x

Acadia Pharmaceuticals Stock FAQ

What is Acadia Pharmaceuticals's quote symbol?

(NASDAQ: ACAD) Acadia Pharmaceuticals trades on the NASDAQ under the ticker symbol ACAD. Acadia Pharmaceuticals stock quotes can also be displayed as NASDAQ: ACAD.

If you're new to stock investing, here's how to buy Acadia Pharmaceuticals stock.

What is the 52 week high and low for Acadia Pharmaceuticals (NASDAQ: ACAD)?

(NASDAQ: ACAD) Acadia Pharmaceuticals's 52-week high was $26.04, and its 52-week low was $12.24. It is currently -5.49% from its 52-week high and 101.06% from its 52-week low.

How much is Acadia Pharmaceuticals stock worth today?

(NASDAQ: ACAD) Acadia Pharmaceuticals currently has 162,625,379 outstanding shares. With Acadia Pharmaceuticals stock trading at $24.61 per share, the total value of Acadia Pharmaceuticals stock (market capitalization) is $4.00B.

Acadia Pharmaceuticals stock was originally listed at a price of $6.70 in May 27, 2004. If you had invested in Acadia Pharmaceuticals stock at $6.70, your return over the last 19 years would have been 267.31%, for an annualized return of 7.09% (not including any dividends or dividend reinvestments).

How much is Acadia Pharmaceuticals's stock price per share?

(NASDAQ: ACAD) Acadia Pharmaceuticals stock price per share is $24.61 today (as of Jun 2, 2023).

What is Acadia Pharmaceuticals's Market Cap?

(NASDAQ: ACAD) Acadia Pharmaceuticals's market cap is $4.00B, as of Jun 3, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Acadia Pharmaceuticals's market cap is calculated by multiplying ACAD's current stock price of $24.61 by ACAD's total outstanding shares of 162,625,379.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.